The dealer licence which was previously under the narcotic control regulations of the controlled drugs and substances act, has now been changed to the recently enacted cannabis act and cannabis regulations.
Showing 25 of 2982
New Zealand listed shares in Synlait opened 12% lower this morning signalling a disappointing result.
Clostridium difficile remains a major medical problem, causing an estimated economic burden of more than US$10 billion globally with 28,000 deaths per year in the US alone.
The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
The company is developing a pipeline of products to treat inflammation and fibrosis.
The agreement underpins the company’s strategy to develop and launch its own branded products by providing higher production volumes and cash flows through ingredient sales.
The GFS solution provides storage and distribution capabilities to automate and streamline the Polaris facility’s nutrient lifecycle planning.
Australian-based YPB Group said Namaste will apply its authenticity product markers to all products on Namaste's e-commerce platforms
The company said planned investment in the period and a softening of growth in China has had a short-term impact on profit growth.
Both companies are also collaborating to connect HeraBEAT heart rate monitors to Hapvida’s electronic medical record systems, allowing nurses and physicians to monitor data in real time.
The company’s lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria.
The company’s CEO James Garner will present to investors in Sydney and Melbourne.
The company is converting biomass to functional industrial sugars to substitute petrochemicals used in manufacturing.
Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.
The i-body technology platform of AdAlta is initially focused on treating fibrotic diseases, such as IPF.
The collaboration agreement is an important advancement for Invitrocue to expand into multiple subtypes of the world’s leading cancer for women.
The easing on restrictions represents a growing acceptance of kava as a natural and safe alternative for managing stress and anxiety.
The two companies have developed breakthrough low GI roti canai, roti and chapatti.
Resonance’s FerriSmart is an artificial intelligence based liver-iron-concentration quantification tool.
The Optima device is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and improves the effectiveness of oral appliance therapy.
The company will also present at the 2019 Biotech Showcase in San Francisco.
After four weeks of treatment with PAT-DX1, treated mice showed 93% less brain metastasis than untreated mice.
The deal will enable Starpharma to leverage its treatment product with growing demand in the US for new and non-antibiotic therapies.
The call will discuss the phase IIb randomised double-blind placebo controlled multicentre study.
The IPO funding will go towards accelerating the company’s testing program to demonstrate performance and safety.